title: [Infectious complications postengrafment in the first year after autologous stem cell transplantation in children].
abstract: BACKGROUND
  Studies on the infectious complications postengrafment in pediatric stem cell transplantation patients are rare. The aim of this study was to assess the incidence, types, outcome and factors affecting late infections.
  
  
  METHODS
  A single-institution retrospective analysis was done of infections recorded in the first year following engrafment in children who underwent autologous stem cell transplantation for solid tumors from January 1991 to December 2000. A systematic antimicrobial chemoprophylaxis of TMP/SMX was administered. Patients who were at high risk for varicella-zona virus infection received prophylactic acyclovir.
  
  
  RESULTS
  Eighty-four assessable patients were enrolled. Fifty-four patients (64%) underwent autologous peripheral blood stem cell transplantation and 30 patients (36%) underwent bone marrow transplantation. Forty-nine episodes of infections were documented in 39 patients (46%) of whom 27 patients (32%) developed infections after the first 100 days post transplantation. Bacterial septicemia occurred in nine patients of whom four patients had a catheter-related septicemia. Twelve patients (14%) developed localized herpes zoster infection. Local fungal infection occurred in five patients. Infection-related death occurred in one patient with non-documented pneumonitis. Univariable analysis showed a correlation between the CD34(+) cell dose <7.5 10(6)/kg and the development of infections (P =0.04). Patients who did not go into remission after transplantation where at high risk for septicemia (P =0.007). Multivariate analysis showed that a history of varicella or pretransplant varicella-zona positivity was the only significant factor for development zoster infection (P =0.01).
  
  
  CONCLUSIONS
  Our study shows that infections in the first year postengrafment following autologous stem cell transplantation for solid tumors have a good prognosis and that the use of TMP/SMX should be the single systematic antimicrobial prophylaxis. The CD34(+) cell dose seems to play a role in preventing late infections.
authors.affiliation: Service d'oncologie pédiatrique, hôpital d'enfants de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France. hassen.bensalah@planet.tn
authors.forename: H
authors.initials: H
authors.lastname: Ben Salah
authors.forename: C
authors.initials: C
authors.lastname: Coze
authors.forename: J C
authors.initials: JC
authors.lastname: Gentet
authors.forename: C
authors.initials: C
authors.lastname: Lautraite
authors.forename: N
authors.initials: N
authors.lastname: André
authors.forename: J L
authors.initials: JL
authors.lastname: Bernard
mesh_terms: D000293:Adolescent; D001424:Bacterial Infections / Q000453:epidemiology* / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D013997:Time Factors; D014777:Virus Diseases / Q000453:epidemiology* / Q000209:etiology